Investigating the effect of pyridostigmine in individuals with poor ovarian response

Investigating the effect of pyridostigmine on controlled ovarian stimulation cycles in individuals with poor ovarian response

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100518003950N8

Enrollment

110

Registered

2023-08-05

Start date

2023-08-06

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility

Interventions

Intervention 1: Intervention group: The intervention group will receive controlled ovarian stimulation treatment with Pyridostigmine at a dose of 120 mg (two 60 mg tablets) orally per day starting fro

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women with a history of poor response to ovarian stimulation in previous cycles who are willing to undergo a new cycle.

Exclusion criteria

Exclusion criteria: BMI more than 30 Respiratory diseases (such as asthma, COPD), renal disease, slow or irregular heartbeat, a history of slow bowel movements and constipation (due to the possibility of delayed drug metabolism), or metabolic disorders. Taking any other cholinergic drug. Endometriosis, stage III-IV History of allergic reactions Taking psychotropic medications and corticosteroids

Design outcomes

Primary

Measure	Time frame
Retrieved Oocytes. Timepoint: 36 hours after receiving the ovulation induction. Method of measurement: Laboratory count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Jafarabadei

Tehran University of Medical Sciences

jafarabadi@tums.ac.ir+98 21 6658 1616

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026